Regarding my naked short learning curve : I have
Post# of 96879
Posted On: 12/19/2015 11:34:26 AM
Regarding my naked short learning curve : I have often mentioned that my training ground was a small pharma called Avanir AVNR
Most of my education happened in the 2006-08 time frame, but it didn't stop there.
You can see it mentioned here in an article about Martin Shkreli:
BigPharmaBackground: Turing Pharmaceuticals made news moderately recently when it suddenly raised the price on Daraprim, a drug used to treat people with compromised immune systems, from $13.50/pill to $750/pill. And then it made news somewhat more recently when the feds arrested Turin CEO Martin Shkreli on securities fraud (involving shenanigans not involving Daraprim*). And just now it’s making news because Shkreli has just resigned from the company, in probably what will be a futile gesture. And so it goes.
But it didn’t go in 2012. As this article from 2014 points out, Shkreli got called out by the notable right-wing shill** Campaign for Responsibility and Ethics in Washington for playing short-selling games in the industry:
In a July 9, 2012, letter to Preet Bharara, the U.S. attorney in Manhattan, CREW listed obscure companies with names such as Avanir Pharmaceuticals (AVNR), Zalicus (ZLCS), and Mesoblast (MSB:AU) that Shkreli had shorted and publicly debased. In the case of yet another company, now known as Navidea Biopharmaceuticals (NAVB), he’d submitted what’s known as a citizen’s petition to the FDA, asking the agency in June 2011 not to approve a lymph-node mapping agent he claimed hadn’t been tested properly. Navidea’s stock dropped 33 percent in a month, to $3.29 on July 1, 2011. “This evidence suggests a pattern of suspicious behavior in the trading of biotech stocks that warrants a thorough investigation,” CREW told Bharara.
The Justice Department and the SEC apparently disagreed. There’s no evidence that either launched a formal probe, and spokesmen for both agencies declined comment.
Why not? Probably because Martin Shkreli is a product of our current system, not an aberration from it
Most of my education happened in the 2006-08 time frame, but it didn't stop there.
You can see it mentioned here in an article about Martin Shkreli:
BigPharmaBackground: Turing Pharmaceuticals made news moderately recently when it suddenly raised the price on Daraprim, a drug used to treat people with compromised immune systems, from $13.50/pill to $750/pill. And then it made news somewhat more recently when the feds arrested Turin CEO Martin Shkreli on securities fraud (involving shenanigans not involving Daraprim*). And just now it’s making news because Shkreli has just resigned from the company, in probably what will be a futile gesture. And so it goes.
But it didn’t go in 2012. As this article from 2014 points out, Shkreli got called out by the notable right-wing shill** Campaign for Responsibility and Ethics in Washington for playing short-selling games in the industry:
In a July 9, 2012, letter to Preet Bharara, the U.S. attorney in Manhattan, CREW listed obscure companies with names such as Avanir Pharmaceuticals (AVNR), Zalicus (ZLCS), and Mesoblast (MSB:AU) that Shkreli had shorted and publicly debased. In the case of yet another company, now known as Navidea Biopharmaceuticals (NAVB), he’d submitted what’s known as a citizen’s petition to the FDA, asking the agency in June 2011 not to approve a lymph-node mapping agent he claimed hadn’t been tested properly. Navidea’s stock dropped 33 percent in a month, to $3.29 on July 1, 2011. “This evidence suggests a pattern of suspicious behavior in the trading of biotech stocks that warrants a thorough investigation,” CREW told Bharara.
The Justice Department and the SEC apparently disagreed. There’s no evidence that either launched a formal probe, and spokesmen for both agencies declined comment.
Why not? Probably because Martin Shkreli is a product of our current system, not an aberration from it
(0)
(0)Nanotech Entertainment Inc. (NTEK) Stock Research Links
Scroll down for more posts ▼